A detailed history of Stifel Financial Corp transactions in Rani Therapeutics Holdings, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 269,768 shares of RANI stock, worth $561,117. This represents 0.0% of its overall portfolio holdings.

Number of Shares
269,768
Previous 134,620 100.39%
Holding current value
$561,117
Previous $511,000 13.89%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.06 - $3.99 $278,404 - $539,240
135,148 Added 100.39%
269,768 $582,000
Q2 2024

Aug 13, 2024

BUY
$3.13 - $7.85 $6,842 - $17,160
2,186 Added 1.65%
134,620 $511,000
Q1 2024

May 13, 2024

BUY
$2.98 - $3.8 $244,860 - $312,238
82,168 Added 163.47%
132,434 $411,000
Q4 2023

Feb 12, 2024

SELL
$1.85 - $3.67 $169,530 - $336,311
-91,638 Reduced 64.58%
50,266 $166,000
Q3 2023

Nov 13, 2023

BUY
$2.17 - $4.44 $141,362 - $289,239
65,144 Added 84.87%
141,904 $307,000
Q2 2023

Aug 14, 2023

BUY
$3.92 - $5.58 $161,672 - $230,135
41,243 Added 116.12%
76,760 $316,000
Q1 2023

May 12, 2023

SELL
$5.07 - $6.89 $887 - $1,205
-175 Reduced 0.49%
35,517 $183,000
Q4 2022

Feb 13, 2023

SELL
$5.51 - $10.02 $27,566 - $50,130
-5,003 Reduced 12.29%
35,692 $210,000
Q3 2022

Nov 14, 2022

SELL
$8.23 - $12.4 $14,814 - $22,320
-1,800 Reduced 4.24%
40,695 $390,000
Q2 2022

Aug 15, 2022

BUY
$8.0 - $14.25 $4,760 - $8,478
595 Added 1.42%
42,495 $439,000
Q1 2022

May 13, 2022

BUY
$12.21 - $23.14 $22,588 - $42,809
1,850 Added 4.62%
41,900 $566,000
Q4 2021

Feb 14, 2022

BUY
$16.09 - $35.0 $33,789 - $73,500
2,100 Added 5.53%
40,050 $655,000
Q3 2021

Nov 15, 2021

BUY
$10.7 - $21.43 $406,065 - $813,268
37,950 New
37,950 $676,000

Others Institutions Holding RANI

About Rani Therapeutics Holdings, Inc.


  • Ticker RANI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,492,000
  • Market Cap $50.9M
  • Description
  • Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed P...
More about RANI
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.